Please login to the form below

Not currently logged in
Email:
Password:

breast cancer

This page shows the latest breast cancer news and features for those working in and with pharma, biotech and healthcare.

AZ and Daiichi get speedy review for rival to Roche’s HER2 drugs

AZ and Daiichi get speedy review for rival to Roche’s HER2 drugs

Like Kadcyla, DS-8201 combines the HER2-targeting of trastuzumab with a cell-killing chemotherapy component designed to improve its ability to kill breast cancer cells. ... ovarian and breast cancer which collectively brought in more than $3bn in

Latest news

  • Lilly’s pegilodecakin fails in long-shot pancreatic cancer trial Lilly’s pegilodecakin fails in long-shot pancreatic cancer trial

    Pancreatic cancer is currently the seventh leading cause of cancer death worldwide, and number three in the US, having overtaken breast cancer a few years ago. ... Earlier-stage trials are ongoing in other advanced solid tumours including melanoma,

  • SMC approves Yescarta and Keytruda, rejects Perjeta SMC approves Yescarta and Keytruda, rejects Perjeta

    In August, Keytruda was also made available as a first-line treatment for patients with untreated advanced lung cancer in England via the Cancer Drugs Fund (CDF). ... The drug received approval from England’s cost-effectiveness watchdog NICE for the

  • Bayer’s Vitrakvi scores first EU tumour-agnostic drug approval Bayer’s Vitrakvi scores first EU tumour-agnostic drug approval

    A tumour-agnostic drug targets specific genetic mutations found across a number of different cancer types. ... This mutation is most commonly found in rare cancers affecting children and adults, including salivary tumours, secretory breast cancer and

  • Roche preps filings for Herceptin/Perjeta combination Roche preps filings for Herceptin/Perjeta combination

    Potential defence against biosimilar competition. A fixed-dose combination of Roche’s antibody blockbusters Herceptin and Perjeta has cleared a phase 3 trial, promising simpler dosing of the breast cancer drugs – ... used in combination, and has seen

  • Tecentriq approved in Europe for triple negative breast cancer Tecentriq approved in Europe for triple negative breast cancer

    Roche can dominate in niche setting. Roche has gained EU-wide approval for Tecentriq in combination with chemotherapy as a treatment for patients with metastatic PD-L1 positive triple negative breast ... TNBC is an aggressive and hard-to-treat subtype of

More from news
Approximately 102 fully matching, plus 667 partially matching documents found.

Latest Intelligence

  • A snapshot of Crescendo Biologics A snapshot of Crescendo Biologics

    What is the central focus of Crescendo’s research? The company is focused on T-cell enhancement to develop new ways to treat difficult cancer types. ... This molecule is designed for the treatment of prostate and other PSMA-positive tumours, such as

  • Leading AstraZeneca’s return to growth in Europe Leading AstraZeneca’s return to growth in Europe

    First we had ovarian cancer, then breast cancer, and our next steps will be for metastatic pancreatic cancer and men with metastatic castration-resistant prostate cancer. ... That’s a measure of its heightened ambitions in oncology, especially as Roche

  • The evolution of real-world studies The evolution of real-world studies

    Pfizer and the FDA shed light on the evolution of RWE in April when breast cancer drug Ibrance secured approval in a new indication on the strength of data from electronic ... The RWE-focused strategy enabled Pfizer to work round the rarity of male

  • The Cystic Fibrosis Buyers’ Club The Cystic Fibrosis Buyers’ Club

    This includes overriding pharma patents – something the group is advocating in relation to three drugs – Vertex’s cystic fibrosis treatment Orkambi, Pfizer’s breast cancer treatment Ibrance and Roche’s breast ... cancer drug Perjeta.

  • Evolving behaviour change Evolving behaviour change

    This month alone I’ve read thought-provoking new research on strategies for empowering older women to raise concerns about breast cancer earlier, and on what makes apps that encourage exercise ... in cancer survivors sink or swim.

More from intelligence
Approximately 1 fully matching, plus 63 partially matching documents found.

Latest appointments

  • Lilly bolsters its oncology team Lilly bolsters its oncology team

    cancer programme, associate director for strategic relations for the Duke Cancer Institute among other roles. ... cancer research, especially metastatic breast cancer, where she has led programmes that resulted in numerous ground-breaking regulatory

  • Ipsen boosts specialty care and R&D leadership teams Ipsen boosts specialty care and R&D leadership teams

    Prior to this, he served as executive director and breast cancer lead for US oncology medical affairs, and held a number of medical affairs oncology positions at Novartis and Bayer.

  • Astellas bolsters oncology clinical development leadership Astellas bolsters oncology clinical development leadership

    breast cancer, leukaemia, lung cancer and prostate cancer. ... of Medicine and the University of Texas MD Anderson Cancer Center.

  • Iris Pauporté joins OSE Immunotherapeutics Iris Pauporté joins OSE Immunotherapeutics

    Pauporté will lead the clinical development of the firm's lung cancer candidate Tedopi, which is currently in phase III trials, and will be responsible for exploring the drug's potential ... She brings over 20 years of biomedical and clinical research

  • Agendia appoints chairman of medical advisory board Agendia appoints chairman of medical advisory board

    Dr Hortobagyi brings over 35 years of experience in clinical and translational research of breast cancer and work as a breast medical oncologist to the molecular cancer diagnostics company. ... He currently also serves as a professor and chair Emeritus

More from appointments
Approximately 0 fully matching, plus 11 partially matching documents found.

Latest from PMHub

More from PMHub
Approximately 3 fully matching, plus 22 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Blue Latitude Health

Blue Latitude Health is a creative marketing consultancy. Founded in 2003, our combination of heritage, approach and capability gives us...

Latest intelligence

Theodora Harold
A snapshot of Crescendo Biologics
PME talks to CEO Theodora Harold...
eyeforpharma Marketing and Customer Innovation Europe
By Richard Springham...
US Drug pricing
The Golden Goose
Why it’s so hard for the US to curb runaway drug prices...

Infographics